An ambitious project led by Vanderbilt University Medical Center investigators aims to use artificial intelligence technologies to generate antibody therapies against any antigen target of interest.

Craft Capital Management LLC acted as underwriter for the Offering (the “Underwriter”). VCL Law LLP acted as U.S. securities counsel to the Company, and Ortoli Rosenstadt LLP acted as U.S. securities ...

Greenhaven Road Capital, an investment management company, released its fourth-quarter 2024 investor letter. A copy of the ...

Advanced Biomed Inc. (the “Company” or “Advanced Biomed”), a biotechnology company focused on early screening and detection, diagnosis and staging, and treatment of cancer, today announced the pricing ...

Signs a strategic collaboration and license agreement to advance novel therapies targeting corticotropin-releasing hormone ...

Under the collaboration agreement, the parties will combine Harbour BioMed's industry-leading technology platform, proprietary dataset and extensive expertise in antibody development with Insilico's ...

(RTTNews) - Intelligent Bio Solutions Inc. (INBS), a New York-based medical technology firm, disclosed on Thursday the pricing details of its previously announced underwritten public offering.